Bayer's drug sales in Asia-Pac up 8.6% in 2016
PHARMACEUTICAL company Bayer reported an 8.6 per cent increase to 4.8 billion euros (S$7.21 billion) in drug sales in the Asia-Pacific region in 2016.
This is its sixth consecutive year of growth - nearly doubled from 2.6 billion euros in 2010.
Claus Zieler, Bayer's senior vice-president and head of commercial operations at its Asia-Pacific pharmaceutical division, said innovation is the foundation of his company's success.
"Our portfolio of innovative medicines, which addresses the unmet medical needs of patients in the Asia-Pacific region, drives our strong business growth today," he said.
Bayer expects global sales of more than 17 billion euros for its pharmaceuticals division in 2017.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
London stocks hit new record at open
Heineken sells more beer in Q1, sticks to outlook
US seeks 36 months’ jail for Binance founder Zhao
China’s Huawei launches new software brand for intelligent driving
Capital A chief Fernandes defers retirement, renews contract for five years
China’s SenseTime soars 36% after unveiling beefier AI model